ISQ remains at the forefront of the cold chain of the first Covid-19 vaccines to arrive in Portugal

As with Pfizer's vaccine on 23 December, ISQ will begin trials today for freezers that will receive the MODERN pharmaceutical vaccine against Covid-19, which was now approved for use in the European Union by the European Medicines Agency. In this case, the arks should be at -20ºC and the tests will take place in the central warehouse, in the area of Coimbra (Arazede). It should be noted that ISQ already carries out conformity assessment and testing of Medical Devices (DM) and Personal Protective Equipment (PPE), supporting manufacturers in the implementation of the conformity assessment procedure and its assessment to be submitted to the supervisory authority. The ISQ also carries out the evaluation tests necessary for community masks, supporting the preparation of the product dossier and the CWA certification process. Additionally, the COVID OUT service is available to the market. COVID-19 can be transmitted by contact with surfaces, where the virus can remain active for several days (WHO Source). ISQ developed this service with a view to identifying, analyzing, evaluating and treating the risk of transmission of Coronavirus SARS-CoV-2. We thus guarantee users of the spaces the confidence and safety necessary for their use by identifying risk factors and critical points, defining a sampling plan for sample collection and analysis, with results in 48 hours, integrated action plan and monitoring the effectiveness of the control measures implemented. In partnership with the ArtSana Group and the Atlantic College, ISQ is still conducting a study to identify the best methodology to be applied in body temperature measurement. The goal is to be able to identify periods of fever and symptom control. Serological tests will also be performed to assess the degree of immunity to the covid-19 virus.